Strides Pharma receives USFDA approval for Prednisone tablets

▴ Strides Pharma receives USFDA approval for Prednisone tablets
Strides Pharma gets USFDA approval for their anti-inflammatory drug Prednisone (tablets)

Drug firm Strides Pharma Science reported,  approval from the US health regulator for generic Prednisone tablets used as an anti-inflammatory medication. Strides Pharma  has received approval for Prednisone tablets USP in the strength of 1 mg from the United States Food & Drug Administration (USFDA), Strides Pharma Science said in a filing to the BSE.

The product is a generic version of Schering Corporation's Meticorten tablets in the same strength, it added. The product will be manufactured at the company's facility at Bengaluru and will be marketed by Strides Pharma Inc in the US market,the filing said.

According to IQVIA MAT July 2020 data, the US market for Prednisone tablets USP 1 mg is approximately USD 12 million (about Rs 88 crore), it added. Prednisone belongs to a class of drugs known as corticosteroids and is used as an anti-inflammatory or an immunosuppressant medication.

It is used in treatment of different conditions such as allergic disorders, skin conditions, ulcerative colitis, arthritis, lupus, psoriasis, or breathing disorders, Strides said. The company has 126 cumulative abbreviated new drug application (ANDA) filings with USFDA of which 89 ANDAs have been approved and 37 are pending approval,it added.

Recently, the company also USFDA approval for Ursodiol tablets USP in the strengths of 250 mg and 500 mg from the United States Food and Drug Administration (USFDA) for treatment of PBC.

PBC is a progressive disease of the liver caused by a buildup of bile within the liver that results in damage to the small bile ducts that drain bile from the liver.

"Strides Pharma Global, Singapore, has received approval for ," the company said in a regulatory filing.

The product is a generic version of Urso 250 tablets, 250 mg, and Urso Forte Tablets, 500 mg, of Allergan Sales, LLC.

Quoting IQVIA moving annual total (MAT) June 2020 data, Strides Pharma Science said the US market for Ursodiol tablets USP, 250 mg and 500 mg, is approximately $35 million.

According to the company , the product will be manufactured at the company''s flagship facility at Bengaluru and will be marketed by Strides Pharma in the US markets.

Tags : #StridesPharmaUSFDAApproval #PrednisoneTablets #IQVIAMat #PBCofLiver #LatestPharmaApprovalNewsUpdateSep4 #LatestPharmaNewsUpdateSep4 #StridesPharmaNewsUpdate

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Remidio with RetinaRisk to Strengthen AI-Driven Diabetic Retinopathy Screening in India and IcelandApril 15, 2025
The New Fertility Crisis: How Modern Lifestyles Are Impacting Your Chances of ParenthoodApril 15, 2025
The Future of Train Travel: Life-saving Healthcare and Regional Cuisine Now on Every TrainApril 15, 2025
The High Price of Healing: How Soaring Surgery Costs Are Bankrupting Indian FamiliesApril 15, 2025
The Price of Survival: Are We Trading Longevity for Disability?April 15, 2025
2,800 Beds. 26 Hospitals. One Vision: Inside the Ujala-Amandeep Power MoveApril 15, 2025
Can Strength Training Rewrite Your Genes? Link Between Muscle Power and Diabetes Prevention.April 15, 2025
Ultra-Processed, Ultra-Powerful: How Modern Food Hijacks Your MindApril 15, 2025
Is Your Health at Risk? The Secret Link Between a Common Parasite and Cervical CancerApril 15, 2025
The Face That Freezes Her Gaze: Why Women Can’t Ignore a Crying InfantApril 15, 2025
Can a Sound Wave Fix Nausea on the Go? A New Hope for Motion Sickness SufferersApril 15, 2025
Gut Instincts, Clear Minds: How Good Bacteria Are Quietly Healing Your MoodApril 15, 2025
When Your Sleep Betrays You: A Deep Dive Into the Nightmare LoopApril 15, 2025
More than 1000 St. George's University Students Secure US Residencies in 2025 MatchApril 15, 2025
Gender justice and health equity are inextricably linked but are programmes linked?April 15, 2025
Berberine Ursodeoxycholate (HTD1801) Consistently Demonstrates Comprehensive Benefits for Patients with Type 2 Diabetes Mellitus, Approaching NDAApril 15, 2025
78% of Indian Youth Embrace Responsibility for Their Healthcare, Burson Global Gen Z ReportApril 14, 2025
Will all children be born free of HIV, syphilis and hepatitis-B by 2030?April 14, 2025
Shattering Boundaries in Gynecological Surgery: Dr. Manjula Anagani Pioneers the Hugo™ RAS System in Asia-PacificApril 12, 2025
Moscow Scientists Develop Advanced Liver Phantom for Radiologists TrainingApril 11, 2025